# EDGAR Filing Document

**Accession Number:** 0001840229
**File Stem:** 0001193125-25-314317
**Filing Date:** 2025-12
**Character Count:** 2823
**Document Hash:** 3a5f3f0d4f9aa51aaf64a688e7fec211
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-314317.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001193125-25-314317

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MiNK Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 212-994-8250

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AgenTus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210112

**MINK THERAPEUTICS, INC.** 

149 Fifth Avenue, Suite 500

New York, NY 10010

December 10, 2025

**<u>VIA EDGAR TRANSMISSION</u>** 

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

---

| | |
|:---|:---|
| **Re:** | **MINK THERAPEUTICS, INC.**  |

---

**<u>Registration Statement on Form S-3 (Registration No.</u> <u>333-291388)</u>** 

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-291388) (as amended, the "Registration Statement") of MiNK Therapeutics, Inc. (the "Company"). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on December 11, 2025, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Elisabeth M. Martin at (617) 948-6018.

If you have any questions regarding the foregoing, please do not hesitate to contact Elisabeth M. Martin at (617) 948-6018 or Wesley C. Holmes at (617) 948-6027, of Latham & Watkins LLP. Thank you in advance for your consideration.

---

| | |
|:---|:---|
|  Very truly yours, | Very truly yours, |
| **MINK THERAPEUTICS, INC.** | **MINK THERAPEUTICS, INC.** |
| By: | /s/ Jennifer S. Buell, Ph.D. |
| Name: | Jennifer S. Buell, Ph.D. |
|  Title: | President and Chief Executive Officer |

---

cc: Peter N. Handrinos, Latham & Watkins LLP

Wesley C. Holmes, Latham & Watkins LLP

Elisabeth M. Martin, Latham & Watkins LLP